Search Results - "Bardiaux, L"

OA3‐AM23‐MN‐36 | Implementation of 100% Pathogen‐Reduced and Extension of Shelf Life of Platelet Concentrates in France: A Retrospective Study on Impact on Platelet Issuing by Richard, P., Morel, P., Malard, L., François, A., Kientz, D., Bardiaux, L., Tiberghien, P., Thibert, J.

Get full text

Evaluation of the success of medical abortion by a plasma hCG control threshold by Vitrant, É, Rolland, A-L, Kyheng, M, Delepine, J, Bardiaux, L, Parent, C, Baffet, H, Catteau-Jonard, S, Robin, G

“…In France, monitoring of the success of medical abortion is recommended 2 to 3 weeks after the procedure. However, there is no clear consensus on the…”
Get full text

Bacterial contamination in platelet concentrates by Pietersz, R. N. I., Reesink, H. W., Panzer, S., Oknaian, S., Kuperman, S., Gabriel, C., Rapaille, A., Lambermont, M., Deneys, V., Sondag, D., Ramírez-Arcos, S., Goldman, M., Delage, G., Bernier, F., Germain, M., Vuk, T., Georgsen, J., Morel, P., Naegelen, C., Bardiaux, L., Cazenave, J.-P., Dreier, J., Vollmer, T., Knabbe, C., Seifried, E., Hourfar, K., Lin, C. K., Spreafico, M., Raffaele, L., Berzuini, A., Prati, D., Satake, M., de Korte, D., van der Meer, P. F., Kerkhoffs, J. L., Blanco, L., Kjeldsen-Kragh, J., Svard-Nilsson, A.-M., McDonald, C. P., Symonds, I., Moule, R., Brailsford, S., Yomtovian, R., Jacobs, M. R.

Get full text

Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect? by Saas, P., Angelot, F., Bardiaux, L., Seilles, E., Garnache-Ottou, F., Perruche, S.

“…Labile blood products contain phosphatidylserine-expressing cell dusts, including apoptotic cells and microparticles. These cell by-products are produced…”
Get full text

Feasibility study for Intercept platelets by Bardiaux, L, Vauzou, S, Olivier, B, Mathieu-Daude, D, Durand, E, Dite, C, Roubinet, F

“…During 3 months, platelet concentrates prepared by "Établissement français du sang Pyrénées-Méditerranée" (Blood bank) were treated with the Intercept process…”
Get more information

The ABLE study: A randomized controlled trial on the efficacy of fresh red cell units to improve the outcome of transfused critically ill adults by Lacroix, J, Hébert, P C, Fergusson, D, Tinmouth, A, Capellier, G, Tiberghien, P, Bardiaux, L

“…Red blood cell units are stored up to 42 days post-collection. The standard policy of blood banks is to deliver the oldest units in order to limit blood…”
Get more information

Prevention of bacterial risk: pathogen inactivation/detection of bacteria by Morel, P, Naegelen, C, Deschaseaux, M, Bardiaux, L

“…Bacterial contamination of blood products remains the most important infectious risk of blood transfusion in 2013. Platelet concentrates (PC) are in cause in…”
Get more information

Control of the bacterial risk of transfusion in France in 2013 by Morel, P, Deschaseaux, M, Bertrand, X, Naegelen, C, Leconte des Floris, M-F, Bardiaux, L

“…Bacterial contamination of blood products (BP) remains the most important infectious risks of blood transfusion in 2013. Platelet concentrates (PC) are the…”
Get full text

Pneumatic tube system for blood products transport by Bardiaux, L, Boulanger, E, Leconte des Floris, M-F, Bourcier, V, Cottier, D

“…Blood product transport from blood bank to the patient care areas of hospitals is a key step in the transfusion process. The pneumatic tube system is now…”
Get full text

What to do in case of adverse event in recipient at the French National Blood Service? by Leconte des Floris, M-F, Pourcelot, L, Hauser, L, Hervé, I, Waller, C, Bardiaux, L, Morel, P

“…One of the main goals of haemovigilance is to gather and analyze adverse events in recipients of blood products in order to improve blood safety. The French…”
Get full text

Prévention du risque bactérien : inactivation des pathogènes/détection des bactéries by Morel, P., Naegelen, C., Deschaseaux, M., Bardiaux, L.

“…La contamination bactérienne des produits sanguins labiles (PSL) reste en 2013 le risque infectieux le plus important de la transfusion sanguine. Les…”
Get full text

Dispositif pneumatique pour le transport des produits sanguins labiles by Bardiaux, L., Boulanger, E., Leconte des Floris, M.-F., Bourcier, V., Cottier, D.

“…Le transport de produits sanguins labiles du service de délivrance vers les services cliniques transfuseurs est une étape clé du processus transfusionnel. Le…”
Get full text

Maîtrise du risque bactérien transfusionnel en France en 2013 by Morel, P., Deschaseaux, M., Bertrand, X., Naegelen, C., Leconte des Floris, M.-F., Bardiaux, L.

“…La contamination bactérienne des produits sanguins labiles (PSL) reste le risque infectieux le plus important de la transfusion sanguine encore en 2013. Les…”
Get full text

Conduite à tenir en cas d’effet indésirable receveur à l’établissement français du sang by Leconte des Floris, M.-F., Pourcelot, L., Hauser, L., Hervé, I., Waller, C., Bardiaux, L., Morel, P.

“…Une des missions principales de l’hémovigilance est de recenser et d’analyser les effets indésirables chez les receveurs de produits sanguins labiles afin…”
Get full text

Transfusion protocols in hematopoietic stem cell allogeneic transplantation by Bardiaux, L, Assari, S, Babinet, J, Cavelier, B, Raba, M, Redersdorff, J-C, Roubinet, F

“…Hematopoietic stem cell (HSC) allogeneic transplantation is now commonly used as a therapeutic tool in patients with certain types of hematologic malignancies…”
Get full text

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology by Cazenave, J-P., Folléa, G., Bardiaux, L., Boiron, J.-M., Lafeuillade, B., Debost, M., Lioure, B., Harousseau, J-L., Tabrizi, R., Cahn, J.-Y., Michallet, M., Ambruso, D., Schots, R., Tissot, J.-D., Sensebé, L., Kondo, T., McCullough, J., Rebulla, Paolo, Escolar, Gines, Mintz, P., Heddle, N.M., Goodrich, R.P., Bruhwyler, J., Le, C., Cook, R.J., Stouch, B.

“…BACKGROUND: Pathogen reduction of platelets (PRT‐PLTs) using riboflavin and ultraviolet light treatment has undergone Phase 1 and 2 studies examining efficacy…”
Get full text

Consignes transfusionnelles en cas d’allogreffe de cellules souches hématopoïétiques by Bardiaux, L., Assari, S., Babinet, J., Cavelier, B., Raba, M., Redersdorff, J.-C., Roubinet, F.

“…L’allogreffe de cellules souches hématopoïétiques (CSH) est une thérapeutique médicale actuellement largement utilisée dans le traitement de certaines…”
Get full text

De la détection bactérienne à l'inactivation des pathogènes by Morel, P., Deschaseaux, M., Naegelen, C., Bardiaux, L., Leconte des Floris, M.F., Pouthier, F.

“…La contamination bactérienne des produits sanguins labiles (PSL) reste le risque infectieux le plus important de la transfusion sanguine. Les concentrés de…”
Get full text

Évaluation du succès de l’interruption volontaire de grossesse médicamenteuse par un seuil d’hCG sérique by Vitrant, É., Rolland, A.-L., Kyheng, M., Delepine, J., Bardiaux, L., Parent, C., Baffet, H., Catteau-Jonard, S., Robin, G.

Get full text

Evaluation of the success of medical abortion by a plasma hCG control threshold by Vitrant, E., Rolland, A. L., Kyheng, Maéva, Delepine, J., Bardiaux, L., Parent, C., Baffet, H., Jonard Catteau, Sophie, Robin, Geoffroy

“…ObjectivesIn France, monitoring of the success of medical abortion is recommended 2 to 3 weeks after the procedure. However, there is no clear consensus on the…”
Get full text